Puma Biotechnology Inc (PBYI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $401.70M
Last updated: Nov 17, 2026 at 11:06 AM ET
Puma Biotechnology Inc (PBYI) Competitors
The companies most similar to Puma Biotechnology are Precision BioSciences (DTIL), PepGen (PEPG) and Immix Biopharma (IMMX). By market cap, Puma Biotechnology ranks 10th of the 13 companies on this page; Cullinan Oncology LLC (CGEM) is the largest at $667.39M.
Peer Comparison
PBYI's revenue growth of 1.1% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Puma Biotechnology (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Fennec Pharmaceuticals Inc (FENC) | $410.25M | 159.5x | 6.8x | 3.0% | N/A | 57.3% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Peer median | $431.87M | 159.5x | 7.3x | 0.0% | -32.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Puma Biotechnology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Fennec Pharmaceuticals Inc (FENC) | Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. | FENC competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
Frequently Asked Questions About PBYI
Who are Puma Biotechnology's main competitors?
The companies most similar to Puma Biotechnology include Precision BioSciences (DTIL), PepGen (PEPG), Immix Biopharma (IMMX), CytomX Therapeutics (CTMX) and Cullinan Oncology LLC (CGEM), listed from the closest match.
Who is Puma Biotechnology's biggest competitor?
Cullinan Oncology LLC (CGEM) is the largest of the similar companies at $667.39M; Precision BioSciences (DTIL) is the closest match by business profile, size, sector and industry.
How does PBYI stock compare with its competitors?
PBYI's P/E is 15.0x against a peer median of 159.5x; its P/S is 1.6x against a peer median of 7.3x; its net margin is 10.3% against a peer median of 0.0%.
Which of Puma Biotechnology's competitors pays a higher dividend?
Puma Biotechnology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Puma Biotechnology bigger than its competitors?
No. Puma Biotechnology is 10th by market cap among the 13 companies on this page; the largest is Cullinan Oncology LLC (CGEM) at $667.39M.
PBYI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors